{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T07:10:24Z","timestamp":1772521824517,"version":"3.50.1"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Left ventricular hypertrophy (LVH), a hallmark of pathological ventricular remodeling, is highly prevalent and strongly predicts mortality in patients undergoing maintenance hemodialysis (MHD). This study aimed to compare the efficacy of sacubitril\/valsartan (SV) vs. angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers (ACEi\/ARB) on ventricular remodeling in hypertensive MHD patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this single-center retrospective cohort study conducted between January 2023 and June 2025, 111 hypertensive patients undergoing MHD for at least 3 months were divided into SV (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200946) and ACEi\/ARB (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200965) groups based on their antihypertensive regimen. The primary endpoint was the change in left ventricular mass index (LVMI) after 6 months. Secondary endpoints included changes in blood pressure, other echocardiographic parameters, NT-proBNP, and safety outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The mean age was 56.17\u2009\u00b1\u200913.47 years and 68.5% were male. After 6 months, LVMI significantly decreased in the SV group (\u22125.52\u2005g\/m\n                      <jats:sup>2<\/jats:sup>\n                      , 95% CI \u22129.35 to \u22121.69,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.006) but not in the ACEi\/ARB group (1.11\u2005g\/m\n                      <jats:sup>2<\/jats:sup>\n                      , 95% CI \u22123.27 to 5.50,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.615). Two-way repeated measures ANOVA revealed a significant group\u2009\u00d7\u2009time interaction for LVMI (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.033). Both groups achieved significant blood pressure reductions: systolic blood pressure decreased by 9.81 mmHg (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001) in the ACEi\/ARB group and by 10.46\u2005mmHg (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001) in the SV group. New-onset intradialytic hypotension occurred in 7 (6.3%) patients and hyperkalemia in 9 (8.1%) patients, with similar incidences between groups and no treatment discontinuations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Compared to ACEi\/ARB, SV is more effective in reversing ventricular remodeling in hypertensive MHD patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1776823","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T06:49:12Z","timestamp":1772520552000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of sacubitril\/valsartan on ventricular remodeling in patients with hypertension and maintenance hemodialysis: a retrospective cohort study"],"prefix":"10.3389","volume":"13","author":[{"given":"Lili","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Nephrology, The Third Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]},{"name":"Department of Nephrology, Youyang Hospital, a Branch of The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Min","sequence":"additional","affiliation":[{"name":"Department of Ultrasonography, Youyang Hospital, a Branch of The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Ran","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Youyang Hospital, a Branch of The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Youyang Hospital, a Branch of The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luping","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Youyang Hospital, a Branch of The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bayi","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Youyang Hospital, a Branch of The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xue","family":"Ran","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Youyang Hospital, a Branch of The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Ran","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Youyang Hospital, a Branch of The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hejun","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Youyang Hospital, a Branch of The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jurong","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The Third Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaofa","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Youyang Hospital, a Branch of The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1093\/ndt\/gfae040","article-title":"A comparison of the epidemiology of kidney replacement therapy between Europe and the United States: 2021 data of the ERA registry and the USRDS","volume":"39","author":"Stel","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"B2","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41581-022-00616-6","article-title":"Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease","volume":"18","author":"Matsushita","year":"2022","journal-title":"Nat Rev Nephrol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"A6","DOI":"10.1053\/j.ajkd.2019.09.003","article-title":"US Renal data system 2019 annual data report: epidemiology of kidney disease in the United States","volume":"75","author":"Saran","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/ki.1995.22","article-title":"Clinical and echocardiographic disease in patients starting end-stage renal disease therapy","volume":"47","author":"Foley","year":"1995","journal-title":"Kidney Int"},{"key":"B5","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1002\/ejhf.3454","article-title":"Efficacy and safety of angiotensin receptor-neprilysin inhibition in heart failure patients with end-stage kidney disease on maintenance dialysis: a systematic review and meta-analysis","volume":"27","author":"Nguyen","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1016\/j.jacc.2019.08.1017","article-title":"Chronic kidney disease and coronary artery disease: jACC state-of-the-art review","volume":"74","author":"Sarnak","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/ki.2011.223","article-title":"Cardiovascular disease in chronic kidney disease. A clinical update from kidney disease: improving global outcomes (KDIGO)","volume":"80","author":"Herzog","year":"2011","journal-title":"Kidney Int"},{"key":"B8","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.2215\/CJN.04860709","article-title":"Left ventricular mass in chronic kidney disease and ESRD","volume":"4","author":"Glassock","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/nrneph.2016.129","article-title":"Epidemiology, diagnosis and management of hypertension among patients on chronic dialysis","volume":"12","author":"Georgianos","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"key":"B11","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1681\/ASN.0000000000000315","article-title":"Resistant hypertension in dialysis: epidemiology, diagnosis, and management","volume":"35","author":"Georgianos","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","article-title":"2021 Clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"99","year":"2021","journal-title":"Kidney Int"},{"key":"B13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41581-018-0101-8","article-title":"Evolving concepts in the pathogenesis of uraemic cardiomyopathy","volume":"15","author":"Wang","year":"2019","journal-title":"Nat Rev Nephrol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1161\/CIRCRESAHA.124.325488","article-title":"Renal-cardiac crosstalk in the pathogenesis and progression of heart failure","volume":"136","author":"Noels","year":"2025","journal-title":"Circ Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e009992","DOI":"10.1161\/JAHA.118.009992","article-title":"Use of antihypertensive agents and association with risk of adverse outcomes in chronic kidney disease: focus on angiotensin-converting enzyme inhibitors and angiotensin receptor blockers","volume":"7","author":"Ku","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"B16","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/j.1525-139X.2010.00782.x","article-title":"Recurrent circulatory stress: the dark side of dialysis","volume":"23","author":"McIntyre","year":"2010","journal-title":"Semin Dial"},{"key":"B17","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11897-021-00501-6","article-title":"Reverse cardiac remodeling and ARNI therapy","volume":"18","author":"Abboud","year":"2021","journal-title":"Curr Heart Fail Rep"},{"key":"B18","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1161\/HYPERTENSIONAHA.116.08556","article-title":"Effects of sacubitril\/valsartan versus olmesartan on central hemodynamics in the elderly with systolic hypertension: the PARAMETER study","volume":"69","author":"Williams","year":"2017","journal-title":"Hypertension"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e2429237","DOI":"10.1001\/jamanetworkopen.2024.29237","article-title":"Sacubitril-valsartan in patients requiring hemodialysis","volume":"7","author":"Le","year":"2024","journal-title":"JAMA Netw Open"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","article-title":"2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European society of hypertension: endorsed by the international society of hypertension (ISH) and the European renal association (ERA)","volume":"41","author":"Mancia","year":"2023","journal-title":"J Hypertens"},{"key":"B22","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/ehjci\/jev014","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging","volume":"16","author":"Lang","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"B23","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3390\/toxins12030161","article-title":"Cardiac remodeling in chronic kidney disease","volume":"12","author":"Kaesler","year":"2020","journal-title":"Toxins (Basel)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"eadj4846","DOI":"10.1126\/sciadv.adj4846","article-title":"Mapping cardiac remodeling in chronic kidney disease","volume":"9","author":"Kaesler","year":"2023","journal-title":"Sci Adv"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1681\/ASN.V1251079","article-title":"Left ventricular hypertrophy in the renal patient","volume":"12","author":"Middleton","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1097\/01.ASN.0000117977.14912.91","article-title":"Prognostic value of echocardiographic indicators of left ventricular systolic function in asymptomatic dialysis patients","volume":"15","author":"Zoccali","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1001\/jama.2019.12821","article-title":"Association of change in N-terminal pro- B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction","volume":"322","author":"Januzzi","year":"2019","journal-title":"JAMA"},{"key":"B28","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1159\/000538899","article-title":"Treatment with sacubitril\/valsartan effectively manages hypertension and ameliorates left ventricular hypertrophy in hemodialysis patients","volume":"53","author":"Hu","year":"2024","journal-title":"Blood Purif"},{"key":"B29","doi-asserted-by":"publisher","first-page":"14415","DOI":"10.3390\/ijms232214415","article-title":"Role of cardiac natriuretic peptides in heart structure and function","volume":"23","author":"Sarzani","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B30","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1093\/ndt\/gfw433","article-title":"Hypertension in dialysis patients: a consensus document by the European renal and cardiovascular medicine (EURECA-m) working group of the European renal association-European dialysis and transplant association (ERA-EDTA) and the hypertension and the kidney working group of the European society of hypertension (ESH)","volume":"32","author":"Sarafidis","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"B31","doi-asserted-by":"publisher","first-page":"206","DOI":"10.3389\/fmed.2018.00206","article-title":"Uremic cardiomyopathy: a new piece in the chronic kidney disease-mineral and bone disorder puzzle","volume":"5","author":"de Albuquerque Suassuna","year":"2018","journal-title":"Front Med (Lausanne)"},{"key":"B32","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1161\/CIRCHEARTFAILURE.114.001785","article-title":"Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy","volume":"8","author":"von Lueder","year":"2014","journal-title":"Circ Heart Fail"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1776823\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T06:49:13Z","timestamp":1772520553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1776823\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":32,"alternative-id":["10.3389\/fcvm.2026.1776823"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1776823","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"article-number":"1776823"}}